1051375-16-6

We have more than 10 years of experience in custom synthesis of compounds. If you are looking for a supplier or manufacturer of Dolutegravir (CAS No.: 1051375-16-6) please contact us. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Dolutegravir (CAS No.: 1051375-16-6) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	Dolutegravir
Synonyms	GSK1349572； (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide;S/GSK1349572;GSK 1349572;Tivicay;DTG
Molecular Formula	C₂₀H₁₉F₂N₃O₅
Molecular Weight	419.37900
CAS Number	1051375-16-6
purity	≥97%

Application：Dolutegravir (DTG) (CAS No.: 1051375-16-6) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just "572" the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process. On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada. On January 16, 2014, Tivicay was approved by the European Commission for use throughout the European Union.

Hot Tags: